HOUSE BILL 343

J3 (8lr0725)

ENROLLED BILL

—Health and Government Operations/Finance—

Introduced by Delegates Kipke, Beitzel, Benson, Bromwell, Costa, Elliott, George, Hammen, Heller, Holmes, Hubbard, Kach, King, Kullen, Love, McDonough, Pena-Melnyk, Reznik, Riley, Robinson, Sophocleus, and Weldon Weldon, Donoghue, Mizeur, Montgomery, Morhaim, Nathan-Pulliam, Oaks, and Pendergrass

Read and	Examined by	Proofreaders:			
]	Proofrea	der.
				Proofrea	der.
Sealed with the Great Seal and	presented to	the Governor,	for his ap	proval	this
day of	at		_ o'clock,		M.
				Spea	ıker.
	CHAPTER				
AN ACT concerning					
Pharmacy Benefits Managers	– Prescriptic Interchang	_	itution <u>Th</u>	<u>erapeu</u>	<u>ıtic</u>
FOR the purpose of prohibiting a prescription drug for the drug a therapeutic interchange pharmacy benefits manager drug substitution is made; to obtain a certain authorinterchange and to make	ug originally punless certa to disclose corequiring a phorization to m	rescribed or its in conditions ertain informati armacy benefits ake a drug su	agent from are met; ion to a pu s manager bstitution	request requiriest rehaser or its a therape	sting ng a if a gent eutic

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

1

 $\frac{2}{3}$

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.

Italics indicate opposite chamber/conference committee amendments.



1	a drug for a currently prescribed drug unless the pharmacy benefits manager			
2	provides a beneficiary or the beneficiary's representative with certain			
3	information requiring a pharmacy benefits manager or its agent to disclose			
4	certain information to a beneficiary and include a certain insert and a certain			
5	telephone number with the prescription drug dispensed; requiring a pharmacy			
6	benefits manager or its agent to cancel and reverse a therapeutic interchange			
7	under certain circumstances; requiring a pharmacy benefits manager or its			
8	agent to take certain actions if a therapeutic interchange is reversed; requiring			
9	a pharmacy benefits manager to maintain a certain toll-free telephone number;			
10	requiring certain disclosures to comply with certain privacy standards;			
11	requiring a pharmacy benefits manager to establish certain policies and			
12	procedures; making certain provisions applicable to health maintenance			
13	organizations; providing certain penalties; defining certain terms; and generally			
14	relating to regulation of pharmacy benefits managers.			
15	BY adding to			
16	Article – Insurance			
$\overline{17}$	Section 15–1601 and 15–1602 to be under the new subtitle "Subtitle 16.			
18	Pharmacy Benefits Managers"			
19	Annotated Code of Maryland			
20	(2006 Replacement Volume and 2007 Supplement)			
40	(2000 Replacement Volume and 2007 Supplement)			
21	BY adding to			
$\frac{21}{22}$	Article – Health – General			
23	Section 19–706(ppp)			
$\frac{23}{24}$	Annotated Code of Maryland			
$\frac{24}{25}$	(2005 Replacement Volume and 2007 Supplement)			
20	(2000 Replacement Volume and 2007 Supplement)			
26	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF			
$\frac{20}{27}$	MARYLAND, That the Laws of Maryland read as follows:			
21	MARTLAND, That the Laws of Maryland read as follows:			
00	Auticle Turners			
28	Article – Insurance			
20	C			
29	SUBTITLE 16. PHARMACY BENEFITS MANAGERS.			
30	15-1601.			
31	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE			
32	MEANINGS INDICATED.			
33	(2) "BENEFICIARY" MEANS AN INDIVIDUAL ON WHOSE BEHALF A			
34	PURCHASER ENTERS INTO AN AGREEMENT WITH A PHARMACY BENEFITS			
35	MANAGER.			
55	4724 24 14 2 VA 2 VA 2 VA 2 VA			

1	(3) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES"
2	MEANS THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG
3	BENEFITS.
4	(H) "PHARMACY BENEFITS MANAGEMENT SERVICES"
5	INCLUDES:
6	1. PROCUREMENT OF PRESCRIPTION DRUGS AT A
7	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE;
8	2. PROCESSING OF PRESCRIPTION DRUG CLAIMS;
0	
9	3. ADMINISTRATION OF PAYMENTS RELATED TO
10	PRESCRIPTION DRUG CLAIMS; AND
11	4. NEGOTIATING OR ENTERING INTO CONTRACTUAL
12	ARRANGEMENTS WITH PHARMACY PROVIDERS.
14	THE THE PERSON OF THE PERSON O
13	(4) "Pharmacy benefits manager" means a person that
14	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
15	(5) (I) "PURCHASER" MEANS A PERSON THAT ENTERS INTO AN
16	AGREEMENT WITH A PHARMACY BENEFITS MANAGER FOR THE PROVISION OF
17	PHARMACY BENEFITS MANAGEMENT SERVICES.
18	(II) "PURCHASER" INCLUDES THE STATE.
4.0	
19	(B) THE PROVISIONS OF THIS SECTION DO NOT APPLY TO A MANAGED
20	CARE ORGANIZATION AUTHORIZED BY TITLE 15, SUBTITLE 1 OF THE
21	HEALTH - GENERAL ARTICLE.
22	(C) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
23	PRESCRIPTION DRUG FOR THE CURRENTLY PRESCRIBED PRESCRIPTION DRUG
$\frac{25}{24}$	UNLESS:
4 4	UNEEDS:
25	(1) THE SUBSTITUTION IS MADE FOR MEDICAL REASONS THAT
26	BENEFIT THE BENEFICIARY; OR
27	(2) THE SUBSTITUTION RESULTS IN FINANCIAL SAVINGS AND
28	BENEFITS TO THE PURCHASER.
29	(D) IF A PRESCRIPTION DRUG SUBSTITUTION IS MADE UNDER THIS
30	SECTION, THE PHARMACY BENEFITS MANAGER SHALL DISCLOSE TO THE
31	PURCHASER ANY BENEFIT OR PAYMENT:

OCCUPATIONS ARTICLE.

1	(1) RELATED TO THE SUBSTITUTION; AND
2	(2) RECEIVED IN ANY FORM BY THE PHARMACY BENEFITS
3	MANAGER FROM A PHARMACEUTICAL MANUFACTURER OR OTHER PERSON.
4	(E) EXCEPT AS PROVIDED IN SUBSECTIONS (G) AND (H) OF THIS
5	SECTION, A PHARMACY BENEFITS MANAGER SHALL:
6	(1) OBTAIN AUTHORIZATION FROM A PRESCRIBER TO
7	SUBSTITUTE ANOTHER PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED
8	PRESCRIPTION DRUG; AND
9	(2) DISCLOSE TO THE PRESCRIBER:
10	(I) THE COST SAVINGS FOR THE PURCHASER, IF ANY, THAT
11	RESULT FROM THE DRUG SUBSTITUTION;
12	(II) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
13	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
14	SUBSTITUTE DRUG;
15	(HI) THE EXISTENCE OF ADDITIONAL PAYMENTS RECEIVED
16	BY THE PHARMACY BENEFITS MANAGER THAT ARE NOT REFLECTED IN THE
17	COST SAVINGS TO THE PURCHASER;
18	(IV) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
19	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
20	(V) THE CIRCUMSTANCES, IF ANY, AND EXTENT TO WHICH
21	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
22	COMPENSATED; AND
23	(VI) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
24	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS.
25	(F) IF AUTHORIZATION IS GIVEN VERBALLY, A PHARMACY BENEFITS
26	MANAGER SHALL RECORD THE NAME AND TITLE OF THE PRESCRIBER
27	AUTHORIZING THE PRESCRIPTION DRUG SUBSTITUTION.
28	(G) SUBSECTION (E) OF THIS SECTION DOES NOT APPLY IF THE
29	SUBSTITUTION IS FROM A BRAND NAME DRUG TO A GENERIC DRUG, AND THE
30	SUBSTITUTION IS MADE IN ACCORDANCE WITH § 12-504 OF THE HEALTH
31	OCCUPATIONS ARTICLE.

1	(H) SUBSECTION (E)(2) OF THIS SECTION DOES NOT APPLY IF:
2	(1) THE CURRENTLY PRESCRIBED DRUG IS NO LONGER
3	AVAILABLE IN THE MARKET; OR
4	(2) THE SUBSTITUTION IS REQUIRED FOR COVERAGE REASONS
5	BECAUSE THE PRESCRIBED DRUG IS NOT COVERED BY THE BENEFICIARY'S
6	FORMULARY OR PLAN.
7	(I) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
8	PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED PRESCRIPTION DRUG
9	UNLESS THE PHARMACY BENEFITS MANAGER PROVIDES THE BENEFICIARY OF
LO	THE BENEFICIARY'S REPRESENTATIVE THE FOLLOWING:
l 1	(1) UNLESS THE SUBSTITUTION WAS EXEMPTED UNDER
12	SUBSECTION (G) OF THIS SECTION, A NOTIFICATION THAT:
13	(I) THE PHARMACY BENEFITS MANAGER REQUESTED A
L 4	DRUG SUBSTITUTION BY CONTACTING THE BENEFICIARY'S PRESCRIBER; AND
15	(II) THE PRESCRIBER APPROVED THE DRUG SUBSTITUTION;
l 6	(2) THE NAMES OF THE PROPOSED DRUG SUBSTITUTION AND THE
L 7	CURRENTLY PRESCRIBED DRUG;
L 8	(3) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
L9	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
20	SUBSTITUTE DRUG;
21	(4) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
22	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS;
23	(5) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
24	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
25	(6) THE CIRCUMSTANCES, IF ANY, AND THE EXTENT TO WHICH
26	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
27	COMPENSATED;
28	(7) A NOTIFICATION THAT THE BENEFICIARY MAY DECLINE THE
29	DRUG SUBSTITUTION IF THE CURRENTLY PRESCRIBED DRUG REMAINS ON THE
30	BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY ANY
31	DIFFERENCE IN THE COPAYMENT AMOUNT: AND

1	(8) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE WITH
2	THE PHARMACY BENEFITS MANAGER.
3	(J) (1) A PHARMACY BENEFITS MANAGER SHALL CANCEL AND
4	REVERSE A PRESCRIPTION DRUG SUBSTITUTION ON WRITTEN OR VERBAL
5	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
6	BENEFICIARY'S REPRESENTATIVE.
7	(2) IF A PRESCRIBER, THE BENEFICIARY, OR THE BENEFICIARY'S
8	REPRESENTATIVE CANCELS AND REVERSES A DRUG SUBSTITUTION, THE
9	PHARMACY BENEFITS MANAGER SHALL:
10	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
11	CURRENTLY PRESCRIBED DRUG;
12	(II) CHARGE THE BENEFICIARY ONLY ONE COPAYMENT; AND
13	(III) IF A BENEFICIARY WILL EXHAUST THE SUPPLY OF THE
14	CURRENTLY PRESCRIBED DRUG BEFORE A REPLACEMENT SHIPMENT WILL
15	ARRIVE TO THE BENEFICIARY, ARRANGE FOR DISPENSING OF AN APPROPRIATE
16	QUANTITY OF REPLACEMENT DRUGS AT A RETAIL OR INSTITUTIONAL
17	PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
18	(3) A PHARMACY BENEFITS MANAGER MAY NOT BE REQUIRED TO
19	CANCEL AND REVERSE A DRUG SUBSTITUTION IF:
20	(I) THE PRESCRIBED DRUG IS NO LONGER ON THE
21	PURCHASER'S FORMULARY; OR
22	(H) A BENEFICIARY IS UNWILLING TO PAY A HIGHER
23	COPAYMENT OR OTHER COST ASSOCIATED WITH THE PRESCRIBED DRUG.
24	(K) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A TOLL-FREE
25	TELEPHONE NUMBER 24 HOURS A DAY, 7 DAYS A WEEK, FOR PRESCRIBERS,
26	PHARMACY PROVIDERS, AND BENEFICIARIES.
27	(L) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
28	WITH THE PRIVACY STANDARDS OF THE FEDERAL HEALTH INSURANCE
29	PORTABILITY AND ACCOUNTABILITY ACT.
30	(M) ON OR BEFORE APRIL 1, 2009, THE COMMISSIONER SHALL ADOPT
31	REGULATIONS TO IMPLEMENT THIS SECTION.

1 2	(N) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
4	EXCEPTIVE \$10,000 FOR EXCIT VIOLATION OF THIS SECTION.
3	(2) In addition to or instead of assessing a civil penalty,
4	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
5	MAKE RESTITUTION TO ANY PERSON WHO HAS SUFFERED FINANCIAL INJURY
6	BECAUSE OF THE VIOLATION OF THIS SECTION.
7	<u>15–1601.</u>
0	(A) IN MANY CAMPAGNET BETT CONTROL WORD WATER THAT AND ADDRESS.
8 9	(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
9	INDICATED.
10	(B) "AGENT" MEANS A PHARMACY, A PHARMACIST, A MAIL ORDER
11	PHARMACY, OR A NONRESIDENT PHARMACY ACTING ON BEHALF OR AT THE
12	DIRECTION OF A PHARMACY BENEFITS MANAGER.
13	(C) "BENEFICIARY" MEANS AN INDIVIDUAL WHO RECEIVES
14	PRESCRIPTION DRUG COVERAGE OR BENEFITS FROM A PURCHASER.
15	(D) "ERISA" HAS THE MEANING STATED IN § 8–301 OF THIS ARTICLE.
	(D) EITISI IIIS IIIS MERINING SINIED IN 3 0 001 01 IIIIS MITIEDE.
16	(E) "NONPROFIT HEALTH MAINTENANCE ORGANIZATION" HAS THE
17	MEANING STATED IN § 6-121(A) OF THIS ARTICLE.
10	(2)
18	(F) "NONRESIDENT PHARMACY" HAS THE MEANING STATED IN § 12–403
19	OF THE HEALTH OCCUPATIONS ARTICLE.
20	(G) "PHARMACIST" HAS THE MEANING STATED IN § 12-101 OF THE
21	· · · · · · · · · · · · · · · · · · ·
22	(H) "PHARMACY" HAS THE MEANING STATED IN § 12–101 OF THE
23	HEALTH OCCUPATIONS ARTICLE.
24	(1) (1) "DILADMA CALDENTES MANA COMENTO CODATIONS AND ANG.
24	(I) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS:
25	(I) THE PROCUREMENT OF PRESCRIPTION DRUGS AT A
26	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE TO BENEFICIARIES;
27	(II) THE ADMINISTRATION OR MANAGEMENT OF
28	PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR
29	RENEFICIARIES: AND

1	(III) ANY OF THE FOLLOWING SERVICES PROVIDED WITH
2	REGARD TO THE ADMINISTRATION OF PRESCRIPTION DRUG COVERAGE:
3	1. MAIL SERVICE PHARMACY;
4	2. <u>CLAIMS PROCESSING, RETAIL NETWORK</u>
5	MANAGEMENT, AND PAYMENT OF CLAIMS TO PHARMACIES FOR PRESCRIPTION
6	DRUGS DISPENSED TO BENEFICIARIES;
7	3. CLINICAL FORMULARY DEVELOPMENT AND
8	MANAGEMENT SERVICES;
9	4. REBATE CONTRACTING AND ADMINISTRATION;
LO	5. PATIENT COMPLIANCE, THERAPEUTIC
1	INTERVENTION, AND GENERIC SUBSTITUTION PROGRAMS; OR
12	6. <u>DISEASE MANAGEMENT PROGRAMS.</u>
13	(2) "PHARMACY BENEFITS MANAGEMENT SERVICES" DOES NOT
L 4	INCLUDE ANY SERVICE PROVIDED BY A NONPROFIT HEALTH MAINTENANCE
15	ORGANIZATION THAT OPERATES AS A GROUP MODEL, PROVIDED THAT THE
l 6	SERVICE:
L 7	(I) IS PROVIDED SOLELY TO A MEMBER OF THE NONPROFIT
L8	HEALTH MAINTENANCE ORGANIZATION; AND
	(II) IS DUDNICHED WIDOUGH WHE DWEDNAL DWADWAGN
9	(II) IS FURNISHED THROUGH THE INTERNAL PHARMACY
20	OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
21	(J) "PHARMACY BENEFITS MANAGER" MEANS A PERSON THAT
22	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
23	(K) "PHARMACY AND THERAPEUTICS COMMITTEE" MEANS A
24	COMMITTEE ESTABLISHED BY A PHARMACY BENEFITS MANAGER TO:
25	(1) OBJECTIVELY APPRAISE AND EVALUATE PRESCRIPTION
26	DRUGS; AND
27	(9) MAKE DECOMMENDATIONS TO A DUDOUASED DECADDING THE
27 28	(2) MAKE RECOMMENDATIONS TO A PURCHASER REGARDING THE
10	SELECTION OF DRUGS FOR THE PURCHASER'S FORMULARY.

1	(L) (1) "PURCHASER" MEANS THE STATE EMPLOYEE AND RETIREE
2	HEALTH AND WELFARE BENEFITS PROGRAM, AN INSURER, A NONPROFIT
3	HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
4	(I) PROVIDES PRESCRIPTION DRUG COVERAGE OR
5	BENEFITS IN THE STATE; AND
6	(II) ENTERS INTO AN AGREEMENT WITH A PHARMACY
7	BENEFITS MANAGER FOR THE PROVISION OF PHARMACY BENEFITS
8	MANAGEMENT SERVICES.
9	(9) "Dipous cep" poec now include a pencon what provides
	(2) "PURCHASER" DOES NOT INCLUDE A PERSON THAT PROVIDES
10	PRESCRIPTION DRUG COVERAGE OR BENEFITS THROUGH PLANS SUBJECT TO ERISA AND DOES NOT PROVIDE PRESCRIPTION DRUG COVERAGE OR BENEFITS
12	THROUGH INSURANCE, UNLESS THE PERSON IS A MULTIPLE EMPLOYER
12 13	
14	WELFARE ASSOCIATION ARRANGEMENT AS DEFINED IN § 514(B)(6)(A)(II) OF ERISA.
14	EITISA.
15	(M) (1) "THERAPEUTIC INTERCHANGE" MEANS ANY CHANGE FROM
16	ONE PRESCRIPTION DRUG TO ANOTHER.
	OND I MESCHAI TIGH BIVOG TO THEOTIEST
17	(2) "THERAPEUTIC INTERCHANGE" DOES NOT INCLUDE:
18	(I) A CHANGE INITIATED PURSUANT TO A DRUG
19	UTILIZATION REVIEW;
20	(II) A CHANGE INITIATED FOR PATIENT SAFETY REASONS;
21	(III) A CHANGE REQUIRED DUE TO MARKET UNAVAILABILITY
22	OF THE CURRENTLY PRESCRIBED DRUG;
23	(DZ) A CHANCE EDOM A DDAND NAME DDIIC TO A CENEDIC
	(IV) A CHANGE FROM A BRAND NAME DRUG TO A GENERIC DRUG IN ACCORDANCE WITH § 12–504 OF THE HEALTH OCCUPATIONS
24 25	ARTICLE; OR
40	ARTICLE; OR
26	(V) A CHANGE REQUIRED FOR COVERAGE REASONS
27	BECAUSE THE ORIGINALLY PRESCRIBED DRUG IS NOT COVERED BY THE
28	BENEFICIARY'S FORMULARY OR PLAN.
-0	DEFENIE OF CHARGE OF LEAST
29	(N) "THERAPEUTIC INTERCHANGE SOLICITATION" MEANS ANY
30	COMMUNICATION BY A PHARMACY BENEFITS MANAGER FOR THE PURPOSE OF
31	REQUESTING A THERAPEUTIC INTERCHANGE.

15–1602.

32

1	(A) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT REQUEST
2	A THERAPEUTIC INTERCHANGE UNLESS:
3	(1) THE PROPOSED THERAPEUTIC INTERCHANGE IS FOR
4	MEDICAL REASONS THAT BENEFIT THE BENEFICIARY; OR
_	
5 6	(2) THE PROPOSED THERAPEUTIC INTERCHANGE WILL RESULT IN
O	FINANCIAL SAVINGS AND BENEFITS TO THE PURCHASER OR THE BENEFICIARY.
7	(B) (1) BEFORE MAKING A THERAPEUTIC INTERCHANGE, A
8	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL OBTAIN AUTHORIZATION
9	FROM A PRESCRIBER OR AN INDIVIDUAL AUTHORIZED BY THE PRESCRIBER.
10	(C) IN ANY THERAPEUTIC INTERCHANGE SOLICITATION, THE
11	FOLLOWING SHALL BE DISCLOSED TO THE PRESCRIBER:
10	
12	(1) THAT A THERAPEUTIC INTERCHANGE IS BEING SOLICITED;
13	(2) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
14	PRESCRIBED DRUG WILL BE COVERED BY THE PURCHASER;
	,
15	(3) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO BE
16	PAID BY THE BENEFICIARY TO OBTAIN THE PROPOSED DRUG;
4 17	
17	(4) THE CIRCUMSTANCES AND EXTENT TO WHICH HEALTH CARE
18 19	COSTS RELATED TO THE THERAPEUTIC INTERCHANGE WILL BE COMPENSATED; AND
13	AND
20	(5) ANY CLINICALLY SIGNIFICANT DIFFERENCES, AS
21	DETERMINED BY A PHARMACY AND THERAPEUTICS COMMITTEE OF THE
22	PHARMACY BENEFITS MANAGER, WITH RESPECT TO EFFICACY, SIDE EFFECTS,
23	AND POTENTIAL IMPACT ON HEALTH AND SAFETY.
2.4	,
24	(D) WHEN SOLICITING A THERAPEUTIC INTERCHANGE FROM A
25 26	PRESCRIBER, A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT MAKE A
26 27	CLAIM THAT THE THERAPEUTIC INTERCHANGE WILL SAVE THE PURCHASER
27	MONEY UNLESS THE CLAIM CAN BE SUBSTANTIATED.
28	(E) IF THE PHARMACY BENEFITS MANAGER OR ITS AGENT RECEIVES
29	PAYMENT FOR MAKING A THERAPEUTIC INTERCHANGE FROM A
30	PHARMACEUTICAL MANUFACTURER OR OTHER PERSON, INCLUDING THE
31	PHARMACY BENEFITS MANAGER, THAT IS NOT REFLECTED IN COST SAVINGS TO

THE PURCHASER, THE EXISTENCE OF THE PAYMENT SHALL BE COMMUNICATED

$1\\2$	TO THE PRESCRIBER AT THE TIME OF THE THERAPEUTIC INTERCHANGE
4	SOLICITATION.
3	(F) IF A THERAPEUTIC INTERCHANGE OCCURS, THE PHARMACY
4	BENEFITS MANAGER OR ITS AGENT SHALL:
5	(1) DISCLOSE TO THE BENEFICIARY, ORALLY OR IN WRITING:
6	(I) TOTATO TOTAL DITADMACN DENTERING MANACED OF THE
7	(I) THAT THE PHARMACY BENEFITS MANAGER OR ITS AGENT REQUESTED A THERAPEUTIC INTERCHANGE BY CONTACTING THE
8	BENEFICIARY'S PRESCRIBER;
Ü	BEN TO THE STREET STREE
9	(II) THE PRESCRIBER APPROVED THE THERAPEUTIC
10	INTERCHANGE;
11	(III) THE NAMES OF THE ORIGINALLY PRESCRIBED DRUG
12	AND THE DRUG DISPENSED PURSUANT TO THE THERAPEUTIC INTERCHANGE;
13	(IV) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO
14	BE PAID BY THE BENEFICIARY TO OBTAIN THE DRUG DISPENSED PURSUANT TO
15	THE THERAPEUTIC INTERCHANGE;
16	(V) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
17	PRESCRIBED DRUG WILL BE COVERED;
18	(VI) THE CIRCUMSTANCES UNDER AND THE EXTENT TO
19	WHICH HEALTH CARE COSTS RELATED TO THE THERAPEUTIC INTERCHANGE
20	WILL BE COMPENSATED; AND
	<u>, </u>
21	(VII) THAT THE BENEFICIARY MAY DECLINE THE
22	THERAPEUTIC INTERCHANGE IF THE ORIGINALLY PRESCRIBED DRUG REMAINS
23	ON THE BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY
24	ANY DIFFERENCE IN THE COPAYMENT OR COINSURANCE; AND
25	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED:
20	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED.
26	(I) A PATIENT PACKAGE INSERT ABOUT POTENTIAL SIDE
27	EFFECTS; AND
28	(II) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE
29	WITH THE PHARMACY BENEFITS MANAGER.
30	(G) (1) A PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL
31	CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE ON WRITTEN OR VERBAL
$o_{\mathbf{T}}$	

1	INSTRUCTIONS	FROM	A	PRESCRIBER,	THE	BENEFICIARY,	OR	THE
				•		•		

- 2 BENEFICIARY'S REPRESENTATIVE.
- 3 IF A THERAPEUTIC INTERCHANGE IS REVERSED. THE 4 PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL:
- 5 **(I)** OBTAIN A PRESCRIPTION FOR AND DISPENSE THE 6 ORIGINALLY PRESCRIBED PRESCRIPTION DRUG; AND
- 7 (II)CHARGE THE BENEFICIARY NO MORE THAN ONE 8 **COPAYMENT.**
- 9 **(3)** IF THE THERAPEUTIC INTERCHANGE OCCURRED THROUGH A 10 MAIL ORDER PHARMACY AND A BENEFICIARY WILL EXHAUST AN EXISTING 11 SUPPLY OF THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG BEFORE A 12 REPLACEMENT SHIPMENT WILL ARRIVE TO THE BENEFICIARY, THE PHARMACY 13 BENEFITS MANAGER OR ITS AGENT SHALL ARRANGE FOR DISPENSING OF AN 14 APPROPRIATE QUANTITY OF REPLACEMENT PRESCRIPTION DRUGS AT A LOCAL
- 15 COMMUNITY PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
- 16 A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT BE **(4)** 17 REQUIRED TO CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE IF A 18 BENEFICIARY IS UNWILLING TO PAY A HIGHER COPAYMENT OR COINSURANCE 19 ASSOCIATED WITH THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG.
- 20 (H) **(1)** A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A 21TOLL-FREE TELEPHONE NUMBER MONDAY THROUGH SATURDAY FOR 22 PRESCRIBERS, PHARMACIES, PHARMACISTS, AND BENEFICIARIES TO REQUEST 23INFORMATION REGARDING A THERAPEUTIC INTERCHANGE.
- 24**(2)** THE TOLL-FREE TELEPHONE NUMBER SHALL BE ACCESSIBLE 25FROM 8 A.M. UNTIL AT LEAST 8 P.M. EASTERN STANDARD TIME.
- 26 ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY (I)27WITH THE PRIVACY STANDARDS SET FORTH IN STATE AND FEDERAL LAW.
- 28 (J)A PHARMACY BENEFITS MANAGER SHALL ESTABLISH APPROPRIATE 29 POLICIES AND PROCEDURES TO IMPLEMENT THE REQUIREMENTS OF THIS 30 SECTION.
- 31 (K) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT 32 EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.

1	(2) IN ADDITION TO OR INSTEAD OF ASSESSING A CIVIL PENALTY,
2	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
3	MAKE RESTITUTION TO ANY PERSON THAT HAS SUFFERED FINANCIAL INJURY
4	BECAUSE OF A VIOLATION OF THIS SECTION.
5	<u> Article - Health - General</u>
6	<u>19–706.</u>
7	(PPP) THE PROVISIONS OF TITLE 15, SUBTITLE 16 OF THE INSURANCE
8	ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS.
9 10	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2008.
	Approved:
	Governor.
	Speaker of the House of Delegates.
	President of the Senate.